이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Evaluation of the Lung Deposition Rate and Distribution Pattern of Tiotropium Via HandiHalerTM in Healthy Subjects and Patients With Chronic Obstructive Pulmonary Disease (COPD)

2014년 6월 20일 업데이트: Boehringer Ingelheim

γ-Scintigraphic Evaluation of the Lung Deposition Rate and Distribution Pattern of a 99mTc-Labelled Tiotropium Powder Formulation Following Multiple Dose Inhalation of Tiotropium Via HandiHalerTM in Healthy Subjects and Patients With COPD

Primary endpoint: whole lung deposition and in-vivo distribution pattern of a 99mTc-labelled tiotropium powder formulation following inhalation via HandiHalerTM in healthy subjects as well as in patients with mild, moderate and severe COPD

Secondary endpoints: pharmacokinetics, pharmacodynamics (effect on lung function), safety and tolerability

연구 개요

연구 유형

중재적

등록 (실제)

22

단계

  • 3단계

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

40년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  • for healthy subjects and COPD patients:

    • Males or females 40 years of age or older.
    • Subjects/Patients must be able to inhale medication from the HandiHalerTM
    • Subjects/Patients must be able to perform all study-related tests including acceptable pulmonary function tests, and must be able to maintain records during the study period as required in the protocol.
    • All subjects/patients must sign an Informed Consent Form prior to participation in the trial in accordance with ICH-GCP and the local legislation, i.e., the COPD patients must give written informed consent prior to pre-study washout of their usual pulmonary medications.
  • for healthy subjects:

    • Normal spirometry as evidenced by a baseline FEV1 ≥ 80 % of predicted normal value for age, height and sex, and FEV1 ≥ 70% of FVC
    • Lifelong non-smokers or ex-smokers with a non-smoking period of at least five years and a maximum of five pack-years.
  • for COPD patients:

    • All patients must have a diagnosis of relatively stable chronic obstructive pulmonary disease and must fulfil the spirometric criteria of the respective sub-group:

      • Mild COPD: 50% ≤ FEV1 < 70% of predicted normal; FEV1/FVC < 70%.
      • Moderate COPD: 35% ≤ FEV1 < 50% of predicted normal; FEV1/FVC < 70%.
      • Severe COPD: FEV1 < 35% of predicted normal; FEV1/FVC < 70%.

Exclusion Criteria:

  • for healthy subjects and COPD patients:

    • Subjects or patients with clinically relevant abnormal baseline haematology, blood chemistry or urinalysis, if the abnormality defines a disease listed as an exclusion criterion will be excluded.
    • All subjects/patients with serum glutamic-oxaloacetic transaminase (SGOT) > 80 IU/L, serum glutamic-pyruvic transaminase (SGPT) > 80 IU/L, bilirubin >2.0 mg/dL or creatinine > 2.0 mg/dL will be excluded regardless of clinical condition. Repeat laboratory evaluation will not be conducted in these subjects/patients.
    • Subjects/Patients with a recent history (i.e., one year or less) of myocardial infarction.
    • Subjects/Patients with any cardiac arrhythmia requiring drug therapy or who have been hospitalised for heart failure within the past three years.
    • Subjects/Patients with known active tuberculosis.
    • Subjects/Patients with a history of cancer within the last five years.
    • Subjects/Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis.
    • Subjects/Patients who have undergone thoracotomy with pulmonary resection.
    • Patients with any upper respiratory infection in the past six weeks prior to the Screening Visit (Visit 1) or during the run-in period
    • Subjects/Patients with known hypersensitivity to anticholinergic drugs, lactose or any other components of the inhalation capsule delivery system
    • Subjects/Patients with known symptomatic prostatic hyperplasia or bladder neck obstruction.
    • Subjects/Patients with known narrow-angle glaucoma.
    • Subjects/Patients with a history of asthma, allergic rhinitis or atopy or who have a total blood eosinophil count ≥ 600 mm3. A repeat eosinophil count will not be conducted in these subjects/patients.
    • Subjects/Patients with a history of and/or active significant alcohol or drug abuse.
    • Subjects/Patients who have taken an investigational drug within one month or six half lives (whichever is shorter) prior to Screening Visit (Visit 1).
  • In addition, for female subjects/patients:

    • Pregnancy.
    • Positive pregnancy test.
    • No adequate contraception, e.g. oral contraceptives, sterilisation, intra uterine device (IUD).
    • Inability to maintain this adequate contraception during the whole study period.
    • Lactation period.
  • for healthy subjects:

    • Subjects with any significant disease will be excluded. A significant disease is defined as a disease which in the opinion of the investigator may either put the subject at risk because of participation in the study or a disease which may influence the results of the study or the subject's ability to participate in the study.
    • Use of any drugs which might influence the results of the trial (within one week prior to administration or during the trial).
  • for COPD patients:

    • Patients with significant diseases other than COPD will be excluded. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study.
    • COPD patients who regularly use daytime oxygen therapy for more than one hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy.
    • Patients who are currently in a pulmonary rehabilitation programme or who have completed a pulmonary rehabilitation programme in the six week prior to the Screening Visit (Visit 1)
    • Patients who are being treated with oral beta adrenergics or long-acting beta adrenergics such as salmeterol and formoterol.
    • Patients who are being treated with beta blockers.
    • Patients who are being treated with antileukotrienes.
    • Patients who are being treated with cromolyn sodium or nedocromil sodium.
    • Patients who are being treated with antihistamines (H1-receptor antagonists).
    • Patients using oral corticosteroid medication at unstable doses (i.e., less than four weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisolone per day or 20 mg every other day.
    • Patients who are being treated with monoamine oxidase inhibitors or tricyclic antidepressants.
    • Patients with no adequate wash-out period of those medications specified in Section 4.2.2 of the study protocol.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: 티오트로피움

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
Percentage of the total administered radioactivity of 99mTc-labelled tiotropium
기간: Day 15
Day 15

2차 결과 측정

결과 측정
기간
Peak plasma concentration at steady state (Cmax,ss)
기간: Day 14
Day 14
Time to peak plasma concentration at steady state (Tmax,ss)
기간: Day 14
Day 14
Pre-dose plasma concentration (Cpre)
기간: Day 1
Day 1
Area under the curve from 0 to 4 hours at steady state (AUCss,0-4h )
기간: Day 14: 5, 10, 20 min, 1, 2, 4 hours after dosing
Day 14: 5, 10, 20 min, 1, 2, 4 hours after dosing
Renal clearance (CLr)
기간: Day 14: 0-4 hours and 4-8 hours after drug administration
Day 14: 0-4 hours and 4-8 hours after drug administration
Drug concentration (C20min)
기간: Day 15: 20 min after drug administration
Day 15: 20 min after drug administration
Drug concentration (C2h)
기간: Day 15: 2 hours after drug administration
Day 15: 2 hours after drug administration
Change from baseline in forced expiratory volume in the first second (FEV1) in healthy subjects
기간: Baseline (day -14), day 15 (pre-dose)
Baseline (day -14), day 15 (pre-dose)
Change from baseline in forced Vital Capacity (FVC) in healthy subjects
기간: Baseline (day -14), day 15 (pre-dose)
Baseline (day -14), day 15 (pre-dose)
Number of adverse events
기간: up to day 38
up to day 38
Change from baseline in puls rate
기간: Baseline, day 28
Baseline, day 28
Change from baseline in blood pressure
기간: Baseline, day 28
Baseline, day 28
Change from baseline in laboratory tests
기간: Baseline, day 28
Baseline, day 28
Change from baseline in 12 lead electrocardiogram (ECG)
기간: Baseline, day 28
Baseline, day 28
Change from baseline in physical examination
기간: Baseline, day 28
Baseline, day 28
Change from baseline in forced expiratory volume in the first second (FEV1) in COPD patients
기간: Baseline (day -14), pre-dose on day 1, 9, 14 (pre-dose and 0.5, 1, 2, and 3 hours after dosing), 15 and 28
Baseline (day -14), pre-dose on day 1, 9, 14 (pre-dose and 0.5, 1, 2, and 3 hours after dosing), 15 and 28
Change from baseline in forced Vital Capacity (FVC) in COPD patients
기간: Baseline (day -14), pre-dose on day 1, 9, 14 (pre-dose and 0.5, 1, 2, and 3 hours after dosing), 15 and 28
Baseline (day -14), pre-dose on day 1, 9, 14 (pre-dose and 0.5, 1, 2, and 3 hours after dosing), 15 and 28
Pre-dose plasma concentration in steady state (Cpre,ss)
기간: day 9, 14, 15
day 9, 14, 15
Area under the curve from 0 to 8 hours at steady state (AUCss,0-8h )
기간: Day 14: 5, 10, 20 min, 1, 2, 4, 8 hours after dosing
Day 14: 5, 10, 20 min, 1, 2, 4, 8 hours after dosing
Amount excreted into urine from 0 to 4 hours (Aess,0-4h)
기간: Day 14: 0-4 hours, day 15: 0-4 hours
Day 14: 0-4 hours, day 15: 0-4 hours
Amount excreted into urine from 0 to 8 hours (Aess,0-8h)
기간: Day 14: 0-8 hours, day 15: 0-8 hours
Day 14: 0-8 hours, day 15: 0-8 hours

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

유용한 링크

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2002년 5월 1일

기본 완료 (실제)

2002년 10월 1일

연구 등록 날짜

최초 제출

2014년 6월 20일

QC 기준을 충족하는 최초 제출

2014년 6월 20일

처음 게시됨 (추정)

2014년 6월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (추정)

2014년 6월 24일

QC 기준을 충족하는 마지막 업데이트 제출

2014년 6월 20일

마지막으로 확인됨

2014년 6월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다